
PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

A new study found that the Zoster Vaccine Live not only reduced the risk for shingles but also reduced stroke risk by 16% in older adults.

The rising price of antiretroviral therapy for people living with HIV in the United States is a barrier to adherence. It also blunts efforts to achieve higher rates of viral suppression.

The International Health Regulations Emergency Committee decided today that the Ebola outbreak in the Democratic Republic of the Congo remains a PHEIC.

In a scenario where health care preparedness is key, what are the best strategies for US hospitals to pursue?

There could be viable options within a few months, but will it be in time to contain an outbreak?

A new article examines pregnancy outcomes among women who received the rVSV-ZEBOV vaccine in the STRIVE study.

With cases of the novel coronavirus (COVID-19) increasing across the globe, why should we be paying attention to influenza—a respiratory illness that is seen year after year?

Less than 1 in 4 teenage boys considered at-risk ever received an HIV test in a recent study.

A new retrospective study provides more evidence that a single HPV vaccine dose may be effective in preventing cervical cancer.

The fact remains that this strain of coronavirus is not highly contagious; it behaves very similarly to other infectious viruses by targeting mainly the weak and/or immunocompromised portions of the population.

The PRIMVAC placental malaria vaccine candidate was found to be safe and immunogenic.

A phase 1 clinical trial suggests that the m102.4 antibody is well tolerated and safe for use as a treatment against henipaviruses.

Does employing the universal use of gloves and gowns decrease the acquisition of antibiotic-resistant gram-negative bacteria?

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of February 2, 2020.

We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

Screening for 2019 novel coronavirus continues around the world. A new research letter on the clinical characteristics of 13 patients sheds light on the nature of cases outside of Wuhan, China.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Despite new treatment options with a lower theoretical risk, approximately 40% of patients with HCV experienced a drug-drug interaction.

Rebiotix has announced that it has completed enrollment of a phase 3 clinical trial for RBX2660.

Treatment with bezlotoxumab resulted in a statistically significant reduction of recurrent C diff in cancer patients, according to a new study.

February 7th is commemorated each year to highlight the impact that HIV and AIDS has on the black or African American population in the United States.

The first strain of influenza virus a person is exposed to in early childhood impacts their ability to fight flu for life. The phenomenon is known as antigenic imprinting.

The US Department of Health and Human Services announced that it is expanding an existing collaboration with Regeneron Pharmaceuticals in order to pursue a treatment for the 2019 novel coronavirus.

HIV-2 infections remain rare in the United States, but the CDC continues to recommend an HIV-1/HIV-2 differentiation test as a second step in testing.

An article concludes that there has been human-to-human transmission among close contacts since the middle of December 2019.

NIAID and partner organizations have discontinued HIV vaccination in a South Africa based experimental trial.

Gilead Sciences is collaborating with Chinese, US, and global health officials in order to investigate the safety and efficacy of their investigational antiviral compound remdesivir against the novel coronavirus.

There have been more than 19 million cases of influenza recorded in the United States over the 2019-20 flu season.

A study and commentary in The Lancet highlight unique challenges posed by controlled-release drugs.